

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

390		
391	Template: CHF> Meds	
392	Inotropics	
	<input type="checkbox"/> Lanoxin 0.25 mg, QD ▽	
393	ACE Inhibitors	
	<i>Clinical Trials prove that ACEI, with diuretics, improve survival and exercise tolerance and decrease Sx, disease progression, and hospitalization in all grades of CHF. <REFS></i>	394
	<input type="checkbox"/> Enalapril 5 mg, BID ▽	
	<input type="checkbox"/> Lisinopril 10 mg, QD ▽	
	<input type="checkbox"/> Bumetanide 1 mg, Q AM ▽	
	<input type="checkbox"/> Benazepril 10 mg, QD ▽	
	Diuretics	
	<input type="checkbox"/> Furosemide 40 mg, Q AM ▽	
	<input type="checkbox"/> Hydroflumethiazide 50 mg, Q AM ▽	
	Vasodilators	
	<input type="checkbox"/> Isosorbide dinitrate, 40 mg, BID ▽	
	<input type="checkbox"/> Erythryl tetranitrate 10 mg, QID ▽	
	<input type="checkbox"/> Hydralazine 25 mg, QID ▽	

FIG. 7




FIG. 8

US 2007/024460




FIG. 9




FIG. 10




FIG. 11




FIG. 12